EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dupilumab modulates type II IL-4/IL-13 receptor-expressing immune cells in eosinophilic chronic rhinosinusitis

Yuri Sonobe, Tomohisa Iinuma, Kota Kokubo, Masahiro Kiuchi, Chiaki Iwamura, Masahiro Nemoto, Takahisa Hishiya, Atsushi Sasaki, Kaori Tsuji, Kanae Ohishi, Kohei Kusakari, Sayaka Sekino und 10 weitere

Journal of Allergy and Clinical Immunology · 2026-11

DOI: 10.1016/j.jaci.2026.10.021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2026-11. Verfasst von Yuri Sonobe und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan; Department of Otorhinolaryngology, Head and Neck Surg…. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AMED, Naito Foundation, Takeda Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Eosinophilic chronic rhinosinusitis (eCRS) is a refractory type 2 inflammatory disease characterized by nasal polyp formation and eosinophilic infiltration. Although dupilumab, an IL-4Rα-blocking antibody, demonstrates clinical efficacy, its cellular mechanisms within nasal polyps remain unclear. OBJECTIVE: To define the cell type-specific effects of dupilumab in eCRS, we examined IL-4/IL-13 receptor-dependent transcriptional responses in tissue-resident immune cells. METHODS: Nasal polyp and peripheral blood samples were collected from five patients with eCRS before and after dupilumab treatment. Single-cell RNA sequencing on four paired cases, spatial transcriptomics, and immunostaining were performed. In vitro stimulation of human conventional dendritic cells (cDCs) validated IL-4/IL-13-regulated pathways. RESULTS: Dupilumab improved symptoms and attenuated eosinophilic inflammation. Across annotated populations, the number of differentially expressed genes correlated positively with pre-treatment IL13RA1 expression. Accordingly, myeloid cells, particularly cDCs, which predominantly express type II IL-4/IL-13 receptors, showed the broadest transcriptional changes, including downregulation of ALOX15; ALOX15 inhibition abrogated IL-4/IL-13-induced CCL13 and CCL22 expression in cDCs. After treatment, pathogenic Th2 cell subset expressed lower IL1RL1 and AREG. IGHE and IL4R expression in CD23-positive B cells declined, as did PRDM1 and ELL2 in plasma cells. In one paired case, spatial analysis identified fewer TLS-like aggregates and lower detection of ALOX15 and IGHE transcripts after treatment. CONCLUSION: Dupilumab preferentially remodels type II IL-4/IL-13 receptor-expressing immune cells, particularly polyp cDCs, while selectively reprogramming Th2, B, and plasma cells. Identification of ALOX15 as a candidate mediator in cDCs provides mechanistic insight that may inform optimization of type 2-targeted therapy in eCRS.

Schlagwörter

Stichwörter der Autor:innen

ALOX15CCL13CCL22Eosinophilic chronic rhinosinusitisconventional dendritic celldupilumabnasal polypspatial transcriptomicstertiary lymphoid structuretype II IL-4/IL-13 receptor

Autor:innen und Institutionen

  • Department of Immunology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan; Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Ja…
  • Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan. Electronic address: iinuma-t@chiba-u.jp.
  • Department of Immunology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
  • Department of Immunology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan; Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University, Chiba 260-8670, Japan.
  • Department of Respiratory Medicine and Infection Disease, Uonuma Kikan Hosipital Niigata University Community-Based Medical Education Center, Niigata 949-7302, Japan.
  • Institute for Advanced Academic Research, Chiba University, Japan; Research Institute of Disaster Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan.

Förderung

  • AMED
  • Naito Foundation
  • Takeda Science Foundation
  • JST
  • Government of Japan Ministry of Education Culture Sports Science and Technology

Zitieren

APA

Sonobe, Y., Iinuma, T., Kokubo, K., Kiuchi, M., Iwamura, C., Nemoto, M., Hishiya, T., Sasaki, A., Tsuji, K., Ohishi, K., Kusakari, K., Sekino, S., Hiramoto, T., Shinmi, R., Koya, T., Onodera, A., Kimura, M. Y., Motohashi, S., Yonekura, S., …, & Hirahara, K. (2026). Dupilumab modulates type II IL-4/IL-13 receptor-expressing immune cells in eosinophilic chronic rhinosinusitis. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2026.10.021

Vancouver

Sonobe Y, Iinuma T, Kokubo K, Kiuchi M, Iwamura C, Nemoto M, et al. Dupilumab modulates type II IL-4/IL-13 receptor-expressing immune cells in eosinophilic chronic rhinosinusitis. Journal of Allergy and Clinical Immunology. 2026. doi:10.1016/j.jaci.2026.10.021

BibTeX
@article{Sonobe2026,
  author = {Sonobe, Yuri and Iinuma, Tomohisa and Kokubo, Kota and Kiuchi, Masahiro and Iwamura, Chiaki and Nemoto, Masahiro and Hishiya, Takahisa and Sasaki, Atsushi and Tsuji, Kaori and Ohishi, Kanae and Kusakari, Kohei and Sekino, Sayaka and Hiramoto, Takuto and Shinmi, Rie and Koya, Toshiyuki and Onodera, Atsushi and Kimura, Motoko Y and Motohashi, Shinichiro and Yonekura, Syuji and Nakayama, Toshinori and Hanazawa, Toyoyuki and Hirahara, Kiyoshi},
  title = {Dupilumab modulates type II IL-4/IL-13 receptor-expressing immune cells in eosinophilic chronic rhinosinusitis},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2026},
  doi = {10.1016/j.jaci.2026.10.021}
}
Kostenlos starten →